Abstract Purpose To evaluate total plasma homocysteine level during the acute phase of central retinal vein occlusion (CRVO) in the Iranian population and determine whether hyperhomocysteinemia is also a risk factor for CRVO. Methods Fifty-four patients with recently diagnosed CRVO were studied. Their fasting total plasma homocysteine level was compared with a matched control group of 51 patients evaluated in the same clinic for a non-retinal disease diagnosis. Results The mean total plasma homocysteine level was 14.76 ± 7.67 mmol/l in cases, and 11.42 ± 3.74 mmol/l in control subjects. It showed a significant difference (P = 0.005) in mean plasma homocysteine level between cases and control group. Odds ratio of CRVO for individuals with hyperhomocysteinemia was 2.88 (95% CI = 1.08À7.71 and P = 0.03). The overall multivariable-adjusted odds of CRVO in participants with plasma homocysteine l e v e l a b o v e 1 5 m m o l / l w a s 4 . 7 1 ( 9 5 % CI = 1.46À15.19 and P = 0.009) Hyperhomocysteinemia was not statistically different in each age group (< 60 years: 27%, 61À70 years: 33.3%, 71À80 years: 31.6%, > 81 years: 33.3%, Chi-square test, P = 0.98). Conclusion Elevated total plasma homocysteine level is an independent risk factor for CRVO in Iranian population. In addition to an evaluation of all conventional cardiovascular risk factors, measurement of total homocysteine for evidence of hyperhomocysteinemia may be important in the initial investigation and management of patients with CRVO.
Introduction
Homocysteine, is an intermediary metabolite of the essential dietary amino-acid methionine, metabolized by remethylation to methionine or by trans-sulfuration to cysteine. In the remethylation pathway, homocysteine is methylated to methionine by the enzyme methionine synthase. The methyl group acquired from 5-methyl tetrahydrofolate and Cobalamin (vitamin B12) is essential for this reaction [1, 2] .
Mean plasma homocysteine level shows a great inter-country variation ranging from 6 mmol/l, in Japan to 13 mmol/l, in South Africa [3] . Hyperhomocysteinemia refers to mild to moderate elevation of the amino acid homocysteine in blood or plasma. It may be caused by genetic determinants [4] , lifestyle determinants [5] (diet, coffee consumption), medications [6] (methotrexate), and clinical conditions [7] such as inadequate plasma concentrations of folate or B-vitamins which are account for nearly two-thirds of all cases of hyperhomocysteinemia in adults [8] .
It is now well documented that elevation of total plasma homocysteine level in a fasting state is associated with an increased risk of cardiovascular disease; such as myocardial infarction [9, 10] , stroke [11, 12] , and carotid intimal-medial wall thickening [13] . Extensive research of recent decade has been shown that, it is an independent risk factor for vascular disease similar to smoking or hyperlipidemia [9, 10] .
Recently hyperhomocysteinemia has also been implicated as an important modifiable potentially risk factor for retinal vein occlusions, especially central retinal vein occlusion (CRVO), which is among the most important causes of vision loss [14, 15, 16, 17, 18, 19, 20, 21, 22] . However data from some recent studies do not confirm this association [23, 4, 25, 26, 27, 28] ; and it has not been reported in Iranian population yet. In a typical daily Iranian diet the consumption of fresh fruits, vegetables, fresh herbs, tea, bread and rice is comparatively higher than a typical diet in Western Europe and the US. In a recent study lower homocysteine levels observed in our population as compared to other populations [29] . The mean plasma homocysteine level in CRVO may also be subsequently lower in our population.
Thus we conducted a study to evaluate total plasma homocysteine level during the acute phase of CRVO compared with a matched healthy group in Iranian population, and also determine whether hyperhomocysteinemia is a risk factor for CRVO.
Patients and methods
We conducted a case-control study on 105 individuals chosen among patients referred to Farabi ophthalmology center over a period of two years (March 2003 to February 2005 . The study was reviewed and approved by the ethics committee of the medical faculty of Tehran University of medical sciences. Participants had no history of major systemic illness, evidence of vasculitits, renal, hepatic or thyroid disease, cardiomyopathy, pregnancy, and chronic alcohol abuse.
The study group contained 54 patients presenting with CRVO in recent one month, acute phase of the disease. CRVO was considered to be present if there were intra retinal hemorrhages in all four retinal quadrants surrounding the optic disk and scattered up to the periphery with venous dilation and tortousity. Control subjects were adult patients who evaluated in the same clinic for a non-retinal disease diagnosis like cataract and nasolacrimal duct obstruction. Controls were matched the study group patients in potential confounding factors such as age, sex, systemic hypertension, diabetes mellitus, and smoking states. Informed consent was also taken for total plasma homocysteine level in this group.
The patients received complete ophthalmic and medical examinations as well as laboratory evaluation, including clotting tests (prothrombin time, partial thromboplastin time, and bleeding time). Fasting total plasma homocysteine level was measured in all patients by high-performance liquid chromatography. Hyperhomocysteinemia was defined as a total plasma homocysteine level above 15 mmol/l.
Descriptive statistics were used to report demographic characteristics with SPSS statistics package version 13.5. The Chi-square test and Student t-test were used to compare the groups on qualitative and quantitative variables, respectively. The adjusted odds ratio was calculated as an estimate of the relative risk of CRVO for individuals with hyperhomocysteinemia. Multivariable-adjusted analyses controlled for statistically significant confounding variables of age, sex, hypertension, smoking history and serum creatinine, cholesterol, and triglyceride.
Results
Fifty-four patients (22 females, 32 males) with CRVO were enrolled in the study. The control group included 51 individuals (22 females, 29 males). Analyses were performed on 105 participants with complete information on CRVO status and total plasma homocysteine level. Age and sex were not significantly different in two groups. Potential confounding risk factors such as diabetes mellitus, hypertension, smoking, and serum creatinine, cholesterol, and triglyceride levels were also comparable in two groups. Patients' characteristics are shown in the Table 1 . The mean total plasma homocysteine level was 14.76 ± 7.67 mmol/l in cases, and 11.42 ± 3.74 mmol/l in control subjects. It showed a significant difference (P = 0.005) in mean plasma homocysteine level between the cases and control group.17 of 54 patients (31.5%), presented with CRVO, had total plasma homocysteine above 15 mmol/l, but only 7 of 51 (13.7%) control subjects. This difference was statistically significant (P = 0.03).
Total homocysteine level above 15 mmol/l was nearly 2.5 times more common in patients with CRVO compared with healthy controls. In univariate analyses, odds ratio (OR) of central retinal vein occlusion for individuals with hyperhomocysteinemia was 2.88; (95% CI = 1.08À7.71 and P = 0.03).
Adjusted odds ratios of different variables are shown in Table 2 . The overall multivariable-adjusted odds of CRVO in participants with plasma homocysteine level above 15 mmol/l was 4.71; (95% CI = 1.46À15.19 and P = 0.009). Each 1 mmol/l increases in homocysteine was associated with significant increased odds for CRVO 0.87; (95%CI = 0.79À0.97, P = 0.01). Hyperhomocysteinemia was not statistically different in each age group (<60 years: 27%, 61À70 years: 33.3 %, 71À80 years: 31.6%, > 81 years: 33.3%, Chi-square test, P = 0.98).
Discussion
The result of this study demonstrated a clinically important and statistically significant association between the presence of hyperhomocysteinemia and central retinal vein occlusion. Compared with the control group, mean plasma total homocysteine levels were significantly higher in patients with retinal vascular occlusive disease (11.42 mmol/l versus 14.76 mmol/l). This is the first study to document that elevated plasma homocysteine level is an independent risk factor for CRVO in Iranian population.
Numerous studies have documented that hyperhomocysteinemia is a risk factor for cardiovascular disease [9, 10, 11, 12, 13, 22] . Elevated total homocysteine is both an independent risk factor for atherosclerotic vascular disease [9, 10] and interacts with other risk factors such as smoking and hypertension to increase cardiovascular disease risk [30] . The exact mechanism by which high plasma concentrations of homocysteine induce arterial and venous thrombosis is still not clear. There is evidence that homocysteine causes endothelial injury and dysfunction by increasing the production of free radicals generated from the oxidation of homocysteine and subsequent peroxidation. Homocysteine also stimulates the proliferation of vascular smooth muscle cells and inhibits the growth of vascular endothelial cells. This combination could lead to atherosclerosis. Other possible mechanisms of thrombosis in hyperhomocysteinemia include increased platelet adhesiveness, activation of the coagulation cascade, and impaired nitric oxide production from endothelial cells [1, 2] . Because the central retinal vein shares a common, fibrous adventitia with the central retinal artery, it is likely that both arterial and venous disease could contribute to the development of a CRVO. Any sclerotic thickening of the central retinal artery could easily compress the adjacent central retinal vein and begin the sequence of events that leads to thrombus formation [30] .
The results of the present study are in line with previous recent studies that recognized hyperhomocysteinemia as a risk factor for retinal vascular occlusive disease especially CRVO [14, 15, 16, 17, 18, 19, 20, 21, 31, 32] . However, most of these studies were retrospective [14, 20, 21] , subjects were not fasting at the time of homocysteine measurement [14] , Cases and controls were not fully matched [14, 21] , and homocysteine was not measured at the time of the acute retinal vascular occlusion [14] . This possible bias would result in lower values for the patients with central retinal vein occlusion. Further studies, including two very recent; found no correlation between CRVO and homocysteine [23, 24, 25, 26, 27, 28] . One recent study suggests that the homocysteine plasma level is not a primary and independent risk factor for central retinal vein occlusion, but is more likely a marker of atherosclerosis and the consequence of other well-established risk factors [28] .
Our study adds further support for a cardiovascular risk profile for persons with CRVO in the Iranian population. These results also support the screening of all patients with CRVO for possible hyperhomocysteinemia.
Differing mean plasma homocysteine values for healthy people from various countries have been reported and range from 6 mmol/L in Japan to 13 mmol/L in South Africa [3] . The reason for intercountry variations of plasma homocysteine is not clear, but Alfthan [3] , argued that these differences are real and not due to non-compatible sampling and assay procedures. A lower homocysteine level reported in our country [29] is comparable with values obtained in France, Spain and Japan [3] . Geographical variation in fruit and vegetable intakes, particularly in dietary folate, might explain these inter-country differences. In a typical daily Iranian diet the consumption of fresh fruits, vegetables, fresh herbs, tea, bread and rice is comparatively higher than a typical diet in Western Europe and the US. This might explain lower homocysteine levels observed in Iranians as compared to other populations [29] . Nevertheless, in our study, mean total plasma homocysteine level was significantly higher in cases, than control subjects. This was also demonstrated by Gao et al. [33] in a Chinese population in which the homocysteine level is low. However, we failed to find any difference in existence of hyperhomocysteinemia among different ages, whereas other studies [15] demonstrated stronger association in patients younger than 70 years old.
The potential importance of treating underlying cardiovascular risk factors is supported by several reports. Patients with retinal vascular occlusive disease have a significant excess of mortality from coronary and cerebrovascular disease [3, 34, 35] . Unlike other risk factors, hyperhomocysteinemia is readily reversible in most individuals with inexpensive vitamin preparations containing folic acid and vitamins. Vitamin supplementation reduces homocysteine levels regardless of the underlying cause [36, 37] . Folate supplementation is cheap and does not give rise to any major side-effects, raising the possibility that some forms of vascular disease may be easily, safely, and inexpensively treated. It is assumed that by reducing the toxic effect of homocysteine on the blood vessels, the probability of further retinal and systemic vascular occlusion, and therefore the resulting morbidity and mortality will be reduced. It has been shown that homocysteinelowering treatment significantly reduced the risk of vascular events and other sequels of classical hyperhomocysteinemia [37, 38] . However, as it is still controversial, further research to assess this association may be useful. Large-scale randomized trials will be required to confirm that reducing plasma homocysteine level decreases retinal and systemic atherothrombotic vascular disease.
